Ribomycin Sulfate Injection

1. Pharmacology This product has a strong effect on most Gram-positive and Gram-negative bacteria. It has a good antibacterial effect on Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, Shigella, and Salmonella, and its activity is slightly worse than kanamycin. It also has a good effect on some Staphylococci, gonococci, and meningococci. It has a weak effect on Streptococcus and Mycobacterium tuberculosis, and is ineffective against Pseudomonas aeruginosa and anaerobic bacteria. This product is cross-resistant with kanamycin. 2. Toxicology Experimental Animal Guinea Pig Ototoxicity Test Results show that this product has significantly lower hearing and cochlear pathological damage to guinea pigs than kanamycin and gentamicin.

The main component of this product is ribofuranosyl sulfate, and its chemical name is: O-3-D ribofuranosyl-(15)-0-[a-2,6-dideoxy-D-pyranose-glucopyranose-(14)]-a-deoxystreptamine sulfate

Used to treat respiratory tract infections, urinary tract infections, biliary tract infections, etc. caused by Streptococcus, Staphylococcus aureus, Escherichia coli, Proteus, Pneumococcus, and Klebsiella pneumoniae that are sensitive to this product.

Intramuscular injection. Adults: 0.5-0.75g (1-1.5 vials) at a time, twice a day. Children: 20-40mg/kg per day according to body weight, divided into 2 injections. The course of treatment is generally within 10 days and no more than 14 days.

The higher incidence rate includes hearing loss, tinnitus or fullness in the ears (ototoxicity), hematuria, decreased urination frequency or decreased urine volume, loss of appetite, extreme thirst (nephrotoxicity), unsteady gait, dizziness (ototoxicity: vestibule effect), nausea or vomiting (ototoxicity: vestibule effect, nephrotoxicity). The lower incidence rate includes dyspnea, drowsiness or weakness (neuromuscular blockade, nephrotoxicity). Hearing loss, tinnitus or fullness in the ears after discontinuation of the drug indicates possible ototoxicity and requires precautions.

1. It is contraindicated for patients with impaired renal function. 2. It is contraindicated for pregnant women. 3. It is contraindicated for infants and young children. 4. It is contraindicated for patients who are allergic to this product.

Precautions for children: Not for use in infants and young children. Precautions for pregnancy and lactation: Not for use in pregnant women.

1. When used in combination with plasma substitutes such as dextran, glucose, sodium alginate, and other nephrotoxic drugs, renal toxicity may be increased. 2. When used in combination with other aminoglycosides or when applied topically or systemically one after the other, the possibility of ototoxicity, nephrotoxicity, and neuromuscular blocking effects may be increased. 3. When used in combination with neuromuscular blockers, the neuromuscular blocking effect may be aggravated, leading to muscle weakness, respiratory depression, or respiratory paralysis. 4. When used in combination with capreomycin, cisplatin, uric acid, furosemide, or vancomycin, or when applied topically or systemically one after the other, ototoxicity and nephrotoxicity may be increased. 5. When used topically or systemically with cephalothin, renal toxicity may be increased. 6. When used in combination with polymyxin injections, or when applied topically or systemically one after the other, renal toxicity and neuromuscular blocking effects may be increased.

Keep tightly closed in a cool, dark place.

2ml:0.5g (500,000 units)

Tentative 18 months

Anhui LianYi Pharmaceutical Co., Ltd.

• Founded in:

  1999-04-21

• Address:

  No. 60, Renmin Road, Daxin Town, Taihe County, Fuyang City, Anhui Province

• Tax NO.:

  91341200152062681B

• Registered Funds:

  18.18 million yuan

• Website:

  Log in to view

• Email:

  Log in to view